Abstract
Colorectal cancer (CRC) may display innate or acquired chemoresistance, and each is important in determining initial and subsequent lines of systemic treatment. Innate resistance is noted during early therapy phases, while acquired resistance develops during systemic antineoplastic treatment.
To prevent ineffective treatment and to select optimal regimens, there is an urgent need to identify biomarkers associated with therapy response. Therefore, the identification and validation of biomarkers for prediction and monitoring of the response of CRC patients to a specific regimen might shift the therapy towards precision medicine.
In this Research Topic, entitled "Strategies in Overcoming the Chemoresistance in Colorectal Cancer", in a collection of ten papers the authors focused on the different aspects that play significant roles in the therapy efficacy. These studies provided insights into the potential of new therapeutic strategies (Zhang et al., Zheng et al., Hu et al., Jiang et al., Lin et al.), presented new predictive markers (Li et al.) or different prospectives and possibilities of applying adjuvant therapy in rectal cancer patients (Kuo et al.) as well as molecular mechanisms involved in the treatment response of CRC patients (Horak et al., Moretton et al., Liu et al.).